Alterity Therapeutics (PRNAD) Retained Earnings (2009 - 2025)

Alterity Therapeutics (PRNAD) has reported Retained Earnings for 16 consecutive years, with -$153.9 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Retained Earnings fell 6.47% year-over-year to -$153.9 million; the TTM figure through Dec 2025 stood at -$153.9 million (down 6.47% YoY), while the FY2025 annual figure was -$144.7 million, down 2.5% from the prior year.
• Retained Earnings came in at -$153.9 million for Q4 2025 at Alterity Therapeutics, down from -$144.7 million in the prior quarter.
• The five-year high for Retained Earnings was $130.7 million in Q2 2021, with the low at -$153.9 million in Q4 2025.
• Average Retained Earnings over 5 years is -$97.0 million, with a median of -$130.8 million recorded in 2022.
• Across the five-year window, Retained Earnings soared 229.14% in 2021 and slumped 7132.96% in 2024, its largest moves.
• Year by year, Retained Earnings stood at -$128.4 million in 2021, then grew by 3.13% to -$124.4 million in 2022, then decreased by 5.49% to -$131.3 million in 2023, then fell by 10.11% to -$144.5 million in 2024, then fell by 6.47% to -$153.9 million in 2025.
• According to Business Quant data, Retained Earnings over the past three periods registered -$153.9 million, -$144.7 million, and -$144.5 million for Q4 2025, Q2 2025, and Q4 2024 respectively.